ClinicalTrials.gg
RecruitingNCT06181136Updated Nov 2, 2026

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

A Phase 1/2 interventional study of DNL126 and Prophylactic immunomodulatory therapy in Mucopolysaccharidosis Type IIIA, sponsored by Denali Therapeutics Inc.. Recruiting at 4 sites in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Denali Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 2, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Planned enrollment
6th of 23
30 · median 17
Started
2023
with 2 others
Phase 1/2
10 of 43
2 open now
Primary completion
2032-07
later than 14 of 14 live
Registered
37th of 43
by date

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 6th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 1/2, reaches primary completion later than 14 of the 14 other live ones, and was the 37th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). In Part 1, the core study period is 25 weeks (approximately 6 months); followed by an open-label extension (OLE), which extends through Week 97 (approximately 18 months); and a long-term extension (LTE), which extends through Week 241 (Year 5). In Part 2, the core study period is 25 weeks in duration followed by an OLE, which extends through Week 49, and an LTE, which extends through Week 241 (Year 5). Participants with MPS IIIA will be enrolled in three planned cohorts, and additional participants with MPS IIIA may be enrolled in three optional cohorts.

The study will enroll up to approximately 30 participants in total: 26 participants in Part 1 (Cohorts A1, A2, A3, B1, and B2 - not enrolling) and 4 participants in Part 2 (Cohort C1 - actively enrolling).

03

Conditions studied

  • Mucopolysaccharidosis Type IIIA

Keywords

  • Sanfilippo Syndrome
  • MPS IIIA
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of MPS IIIA
  • For Cohorts A2 and C1: No more than 1 participant may have predictors of a slow-progressing phenotype
  • For Cohort A3: Approximately 2 participants will have predictors of the slow-progressing phenotype
  • For Cohort B1: Have a severe phenotype based on having at least one of the following:

    • An older sibling with the same genotype and severe MPS IIIA, in the opinion of the investigator
    • A definitive genotype indicative of severe MPS IIIA, in the opinion of the investigator
    • Clinical symptoms of MPS IIIA prior to 28 months of age that, in the opinion of the investigator, are indicative of severe MPS IIIA
  • For Cohort B2: Are an older sibling of a participant in Cohort B1 (who has already been confirmed to be eligible for dosing) with MPS IIIA, the same causative genotype, and who has severe MPS IIIA in the opinion of the investigator
  • For Cohort C1: Have up-to-date age-specific vaccination status, including SARS-CoV-2 (COVID-19) vaccines, according to country-specific guidelines at the time of the screening visit.

Key Exclusion Criteria:

  • Have unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
  • Have lost the ability to walk independently, in the opinion of the investigator
  • Are unable to take the majority of nutrition via mouth, in the opinion of the investigator
  • For Cohort B only: Are homozygous or compound heterozygous for the N-sulfoglucosamine sulfohydrolase (SGSH) S298P mutation or any other mutation known to be associated with slow-progressing phenotype
  • Have used any CNS-targeted MPS IIIA enzyme replacement therapy (ERT) (eg, intrathecal SGSH or TfR-mediated SGSH delivery to CNS) within 3 months before Day 1
  • Have a prior history of hematopoietic stem cell transplantation
  • Have a prior history of gene therapy
  • Have used genistein or anakinra within 7 days of screening or intended use of genistein or anakinra during the study
  • Have a documented likely pathogenic mutation sufficient to cause disease (eg, taking into account zygosity) of other genes that are known to be associated with developmental delay, seizures, or other significant CNS disorders
  • Have thrombocytopenia, other clinically significant coagulation abnormality, significant active bleeding, or require treatment with an anticoagulant or more than two antiplatelet agents
  • for lumbar punctures
  • Contraindication for MRI scan
  • Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any clinically significant CNS disease that is not MPS IIIA-related within 3 months of screening
  • Have had a ventriculoperitoneal (VP) shunt placed or a clinically significant VP shunt malfunction within 30 days of screening
  • Have any clinically significant CNS trauma or disorder, including severe untreated intracranial hypertension or brain surgery, that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort A1

    Participants with MPS IIIA

    Drug: DNL126

  • Experimental
    Cohort A2

    Participants with MPS IIIA

    Drug: DNL126

  • Experimental
    Cohort A3

    Participants with MPS IIIA

    Drug: DNL126

  • Experimental
    Cohort B1

    Participants with MPS IIIA

    Drug: DNL126

  • Experimental
    Cohort B2

    Participants with MPS IIIA

    Drug: DNL126

  • Experimental
    Cohort C1

    Participants with MPS IIIA

    Drug: DNL126 · Drug: Prophylactic immunomodulatory therapy

Interventions

  • DrugDNL126

    intravenous repeating dose

  • DrugProphylactic immunomodulatory therapy

    Per local prescribing information

06

What researchers measure

Primary outcomes

  1. Part 1: Change from baseline in the natural logarithm of cerebrospinal fluid (CSF) heparan sulfate (HS) concentration

    Time frame: 49 weeks

Secondary outcomes

  1. Part 1: Change from baseline in the natural logarithm of urine HS (normalized to creatinine) concentration

    Time frame: 49 weeks

  2. Part 1: Change from baseline in liver volume multiples of normal

    Time frame: 49 weeks

  3. Part 1: Change from baseline in the natural logarithm of serum neurofilament light chain (NfL) concentration

    Time frame: 73 weeks

  4. Part 1: Participants with CSF HS concentration within the normal range

    Time frame: 49 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2023 (actual). Primary completion is estimated for Jul 2032, 103 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2028 → Jul 2032 and completion Aug 2028 → Jul 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 26, 2023
StartActual
Dec 7, 2023
Primary completionEst.
Jul 2032was Aug 2028
CompletionEst.
Jul 2032was Aug 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 2, 2026
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • UCSF Benioff Children's Hospital Oakland · Oakland, United Statesno status→Recruiting
  • University of Iowa Stead Family Children's Hospital · Iowa City, United Statesno status→Recruiting
  • University of North Carolina at Chapel Hill · Chapel Hill, United Statesno status→Recruiting
  • Baylor College of Medicine and Texas Children's Hospital · Houston, United Statesno status→Recruiting
Nov 2, 2026
Primary completion
Aug 2028→Jul 2032
Nov 2, 2026
Study completion
Aug 2028→Jul 2032
Nov 2, 2026
Enrollment
20 (actual)→30 (estimated)
Nov 2, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedFor CohortCohorts A2 and C1: No more than 1 participant may have predictors of a slow-progressing phenotype
  • AddedFor Cohort C1: Have up-to-date age-specific vaccination status, including SARS-CoV-2 (COVID-19) vaccines, according to country-specific guidelines at the time of the screening visit.
Nov 2, 2026
Interventions
Added Drug: Prophylactic immunomodulatory therapy. Arms added: Cohort C1
Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPart 1: Change from baseline in the natural logarithm of cerebrospinal fluid (CSF) heparan sulfate (HS) concentrationTime frame: 49 weeks
Nov 2, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedPart 1: Change from baseline in the natural logarithm of urine HS (normalized to creatinine) concentrationTime frame: 49 weeks
  • EditedPart 1: Change from baseline in liver volume multiples of normalTime frame: 49 weeks
  • EditedPart 1: Change from baseline in the natural logarithm of serum neurofilament light chain (NfL) concentrationTime frame: 73 weeks
  • EditedPart 1: Participants with CSF HS concentration within the normal rangeTime frame: 49 weeks
Nov 2, 2026
Contact
Study contact now listed: added c•••@dnli.com. See the current contact
Nov 2, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • UCSF Benioff Children's Hospital Oakland · Oakland, United StatesContact added I•••@ucsf.edu · •••3885
  • University of Iowa Stead Family Children's Hospital · Iowa City, United StatesContact added l•••@uiowa.edu · •••8197
  • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact added L•••@med.unc.edu · •••1135
  • Baylor College of Medicine and Texas Children's Hospital · Houston, United StatesContact added v•••@bcm.edu · •••3323Contact added K•••@bcm.edu · •••1421
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • UCSF Benioff Children's Hospital Oakland · Oakland, United Statesno status→Recruiting
    • University of Iowa Stead Family Children's Hospital · Iowa City, United Statesno status→Recruiting
    • University of North Carolina at Chapel Hill · Chapel Hill, United Statesno status→Recruiting
    • Baylor College of Medicine and Texas Children's Hospital · Houston, United Statesno status→Recruiting
    Primary completion Aug 2028→Jul 2032
    Study completion Aug 2028→Jul 2032
    Enrollment 20 (actual)→30 (estimated)
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedFor CohortCohorts A2 and C1: No more than 1 participant may have predictors of a slow-progressing phenotype
    • AddedFor Cohort C1: Have up-to-date age-specific vaccination status, including SARS-CoV-2 (COVID-19) vaccines, according to country-specific guidelines at the time of the screening visit.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPart 1: Change from baseline in the natural logarithm of cerebrospinal fluid (CSF) heparan sulfate (HS) concentrationTime frame: 49 weeks
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedPart 1: Change from baseline in the natural logarithm of urine HS (normalized to creatinine) concentrationTime frame: 49 weeks
    • EditedPart 1: Change from baseline in liver volume multiples of normalTime frame: 49 weeks
    • EditedPart 1: Change from baseline in the natural logarithm of serum neurofilament light chain (NfL) concentrationTime frame: 73 weeks
    • EditedPart 1: Participants with CSF HS concentration within the normal rangeTime frame: 49 weeks
    Interventions Added Drug: Prophylactic immunomodulatory therapy. Arms added: Cohort C1
    Contact Study contact now listed: added c•••@dnli.com. See the current contact
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • UCSF Benioff Children's Hospital Oakland · Oakland, United StatesContact added I•••@ucsf.edu · •••3885
    • University of Iowa Stead Family Children's Hospital · Iowa City, United StatesContact added l•••@uiowa.edu · •••8197
    • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact added L•••@med.unc.edu · •••1135
    • Baylor College of Medicine and Texas Children's Hospital · Houston, United StatesContact added v•••@bcm.edu · •••3323Contact added K•••@bcm.edu · •••1421
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06181136
Lead sponsor
Denali Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Dec 7, 2023
Primary completion
Jul 2032 (estimated)
Completion
Jul 2032 (estimated)
Last update
Nov 2, 2026

Study contacts

Clinical Trials at Denali Therapeutics
Contact
clinical-trials@dnli.com
Email
Ana-Claire Meyer, MD
study director · Denali Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion